Meeting NewsVideo

VIDEO: Novel drug aims to lower episcleral venous pressure to treat glaucoma

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thurein Htoo, MS, MBA, CEO of Qlaris Bio, discusses how the company is targeting episcleral venous pressure in the treatment of glaucoma. QLS-101, Qlaris Bio’s novel topical drug therapy, acts to reduce episcleral venous pressure, therefore reducing IOP.

Glaucoma 360 attendees voted Htoo’s presentation the winner of the Best Pitch Award.

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thurein Htoo, MS, MBA, CEO of Qlaris Bio, discusses how the company is targeting episcleral venous pressure in the treatment of glaucoma. QLS-101, Qlaris Bio’s novel topical drug therapy, acts to reduce episcleral venous pressure, therefore reducing IOP.

Glaucoma 360 attendees voted Htoo’s presentation the winner of the Best Pitch Award.

    See more from Glaucoma 360